STOCK TITAN
  1. Home
  2. News
  3. REPL

Replimune Group Inc - REPL STOCK NEWS

Welcome to our dedicated news page for Replimune Group (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Replimune Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Replimune Group's position in the market.

News
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Rhea-AI Summary
Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
clinical trial
-
News
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Replimune Group, Inc. grants inducement equity awards to Carolyn Trott, the new Senior Vice President, Quality Assurance, comprising a stock option for 75,000 shares and restricted stock units for 50,000 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
News
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Rhea-AI Summary
Replimune Group, Inc. announces leadership changes to support commercialization efforts for RP1 biologics. Sushil Patel to succeed Philip Astley-Sparke as CEO. RP1 BLA submission planned for 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
management
News
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
Rhea-AI Summary
Replimune Group, Inc. announces presentations at AACR Annual Meeting 2024 for RP1 and RP2 oncolytic immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
conferences
-
News
Replimune to Present at Three Upcoming Investor Conferences
Rhea-AI Summary
Replimune Group, Inc. announces participation in three upcoming investor conferences to present oncolytic immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
conferences
-
News
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary
Replimune Group, Inc. (Nasdaq: REPL) announced positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma, demonstrating durability of response. Centrally reviewed 12-month primary analysis data from IGNYTE trial of RP1 in anti-PD1 failed melanoma and biologics license application (BLA) submission expected in 2H 2024. Phase 3 confirmatory trial of RP1 in anti-PD1 failed melanoma skin cancers expected to initiate 2H 2024. Cash runway extended to fund operations into 2H 2026. CEO Philip Astley-Sparke expressed optimism about the potential of RP1 as a safe and effective treatment option for patients with different skin cancers, planning to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024 and explore potential additional submissions based on evolving data from multiple non-melanoma skin cancer studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
earnings
News
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Rhea-AI Summary
DISCO Pharmaceuticals, a specialist biotech company, has emerged from stealth with a transformative surfaceome discovery technology to identify new targets and develop first-in-class drugs for cancer treatment. The company has successfully raised seed financing of EUR 20 million and is backed by a world-leading investor syndicate. DISCO has completed the first-ever map of the surfaceome of Small Cell Lung Cancer and is developing proprietary antibody-based treatments for it. The company is also working on Microsatellite-Stable Colorectal Cancer and has a pipeline of further undisclosed programs. The experienced team, led by CEO Roman Thomas, includes leading biopharma executives Dieter Weinand and Carsten Reinhardt. The company's surfaceome mapping platform has the potential to transform oncology treatment options and improve outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
none
-
News
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Replimune Group, Inc. (Nasdaq: REPL) announced that CEO Philip Astley-Sparke will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The company is a clinical stage biotechnology firm focusing on oncolytic immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
conferences
-
News
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
Rhea-AI Summary
Replimune Group, a clinical stage biotechnology company (NASDAQ: REPL), announced results from the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial. The company also shared a new data snapshot from the IGNYTE cohort of anti-PD1 failed non-melanoma skin cancer (NMSC) patients and data from the ARTACUS trial evaluating RP1 as monotherapy for skin cancer in patients who have had solid organ or hematopoietic cell transplants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.21%
Tags
clinical trial
News
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
Rhea-AI Summary
Replimune Group, Inc. (NASDAQ: REPL) announced updated data from a Phase 1 study of RP2 in metastatic uveal melanoma patients, showing a 29.4% overall response rate and a median duration of response of 11.47 months. The treatment was generally well tolerated with no grade 4 or 5 adverse events. Dr. Joseph Sacco presented the data at the 20th International Congress of the Society for Melanoma Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
none
Stock REPL logo
Replimune Group Inc

Nasdaq:REPL

REPL Rankings

#3172 Ranked by Market Cap
#3660 Ranked by Stock Gains
N/A Ranked by Dividends

REPL Stock Data

438.31M
39.05M
5.8%
113.16%
12.6%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Woburn

About REPL

replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.